Onbrez Brizkhaler: aktual'nye voprosy
- Authors: Avdeev S.N1
-
Affiliations:
- ФГУ НИИ пульмонологии ФМБА России, Москва
- Issue: Vol 14, No 3 (2012)
- Pages: 79-86
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/93594
- ID: 93594
Cite item
Full Text
Abstract
Индакатерол − новый препарат из класса длительно действующих b2-агонистов (ДДБА. Несмотря на то, что в настоящее время современные ДДБА наряду с длительно действующими антихолинергическими препаратами (ДДАХП) рассматриваются как препараты первой линии терапии больных хронической обструктивной болезнью легких (ХОБЛ), все еще ощущается потребность в дальнейшем усовершенствовании этих препаратов, так как многие пациенты с ХОБЛ не достигают оптимального контроля над заболеванием.
Full Text
##article.viewOnOriginalSite##References
- Beeh K.M., Beier J. Indacaterol: a new once daily long - acting beta2 - adrenoceptor agonist. Core Evidence 2009; 4: 37–41.
- Moen M.D. Indacaterol in chronic obstructive pulmonary disease. Drugs 2010; 70: 2269–80.
- Brienza N.S., Amor-Carro Ó, Ramos-Barbón D. An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis 2011; 5: 29–40.
- Yorgancioglu A. Indacaterol in chronic obstructive pulmonary disease. An update for clinicians. Ther Adv Chronic Dis 2012; 3: 25–36.
- GOLD Guidelines. COPD Diagnosis and Management. Global Initiative for Chronic Obstructive Pulmonary Disease (2011). Available from: http://www.goldcopd.com.
- Cazzola M, Calzetta L, Matera M.G. b2 - adrenoceptor agonists: current and future direction. Br J Pharmacol 2011; 163: 4–17.
- Cazzola M, Matera M.G., Lotvall J. Ultra long - acting beta2 - agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–83.
- EMEA European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_Public_assessment_report/human/001114/ WC500053735.pdf. Accessed: March 21, 2012.
- Battram C, Charlton S.J., Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
- Lombardi D, Cuenoud B, Kramer S.D. et al. Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38: 533–47.
- Cazzola M, Calzetta L, Matera M.G. Novel long - acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155: 291–9.
- Pontier J, Percherancier Y, Galandrin S et al. Cholestero l -dependent separation of the b2 - adrenergic receptor from its partners determines signaling efficacy. Insight into nanoscale organization of signal transduction. J Biol Chem 2008; 283: 24659–72.
- Cazzola M, Proietto A, Matera M.G. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010; 46: 139–50.
- Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled b2 - adrenoreceptor agonist. Open Respir Med J 2009; 3: 27–30.
- Tashkin D.P., Cooper C.B. The role of long - acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–59.
- Vogelmeier C, Kardos P, Harari S et al. Formoterol mono - and combination therapy with tiotropium in patients with COPD: A 6-month study. Respiry Mede 2008; 102: 1511–20.
- van Noord J.A., Aumann J.L., Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
- Чучалин А.Г., Овчаренко С.И., Авдеев С.Н. и др. Место препарата Онбрез Бризхалер (индакатерол) в терапии хронической обструктивной болезни легких: заключение экспертного совета. Пульмонология. 2011; 6: 124–5.
- Dahl R. Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use. European Respiratory Society (ERS) Annual Congress 2011. Abstract No. P861.
- Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once - daily in COPD: a doubl e -blind, randomised, 12 - week study. BMC Pulm Med 2010; 10: 11.
- Donohue J.F., Fogarty C, Lotvall J et al. Once - daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
- Kornmann O, Dahl R, Centanni S et al. Once - daily indacaterol vs twice - daily salmeterol for COPD: a placebo - controlled comparison. Eur Respir J 2011; 37: 273–9.
- Dahl R, Chung K.F., Buhl R et al. Efficacy of a new once daily long - acting inhaled b2 - agonist indacaterol versus twice - daily formoterol in COPD. Thorax 2010; 65: 473–9.
- Chapman K.R., Rennard S.I., Dogra A et al. Long - term safety and efficacy of indacaterol, a novel long - acting b2 - agonist, in subjects with COPD: a randomized, placebo - controlled study. Chest 2011; 140: 68–75.
- Korn S, Kerwin E, Atis S et al. Indacaterol once - daily provides superior efficacy to salmeterol twice - daily in COPD: A 12 - week study. Respir Med 2011; 105: 719–26.
- Buhl R, Dunn L.J., Disdier C et al. on behalf of the INTENSITY study investigators. Blinded 12 - week comparison of once - daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38: 797–803.
- Mahler D.A., Buhl R, Owen R et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (<65 or ≥65 years) [abstract no. F93]. Am J Respir Crit Care Med 2010; 181: A4456.
- Donohue J.F., Decramer M, Owen R et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use [abstract no. F75]. Am J Respir Crit Care Med 2010; 181: A4438.
- Kleerup E.C., D’Urzo A, Owen R et al. Once - daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility [abstract no. F76]. Am J Respir Crit Care Med 2010; 181: A4439.
- O’Donnell, Casaburi R, Vincken W et al. Effect of Indacaterol on exercise endu - rance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030–6.
- Donaldson G.C., Wedzicha J.A. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–8.
- Siler T.M., Williams J, Yegen U et al. The effect of once - daily indacaterol on health - related quality of life, rescue medication use, and exacerbation rates in patients with moderate - to - severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 2010; 181: A4430.
- Curtis J.R., Patrick D.L. The assessment of health status among patients with COPD. Eur Respir J Suppl 2003; 41: 36s–45s.
- Jones P.W., Brusselle G, Dal Negro R.W. et al. Health - related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011; 105: 57–66.
- Lipworth B.J. Antagonism of long - acting β-adrenoreceptor agonism. Br J Clin Pharmacol 2002; 54: 231–45.
- Naline E, Trifilieff A, Fairhurst R.A. et al. Effect of indacaterol, a novel long - acting b2 - agonist, on isolated human bronchi. Eur Respir J 2007; 29: 575–81.
- Decramer M, Donohue J, Owen R et al. Indacaterol provides effective bronchodilation in patients with COPD regardless of concomitant ICS use. European Respiratory Society (ERS) Annual Congress 2010. Abstract No. P5555.
- Mahler D.A., D’Urzo A, Peckitt C et al. Combining once - daily bronchodilators in COPD: Indacaterol plus tiotropium versus tiotropium alone. Presented at American Thoracic Society (ATS) International Conference, Denver Colorado, May 2011. Am J Respir Crit Care Med 2011; 183: A1591.
- Sears M.R. Adverse effects of beta - agonists. J Allergy Clin Immunol 2002; 110: S322–S328.
- Worth H, Chung K.F., Felser J.M. et al. Cardio - and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.